18 Aug 2023
Estimating overall survival in people receiving Pharmaceutical Benefits Scheme (PBS)-listed cancer medicines in Australian clinical practice
Estimating overall survival in people receiving Pharmaceutical Benefits Scheme (PBS)-listed cancer medicines in Australian clinical practice
15 Aug 2023
Update from the Health Technology Assessment Policy and Methods Review Reference Committee – August 2023
Update from the Health Technology Assessment Policy and Methods Review Reference Committee – August 2023
14 Aug 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – August 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – August 2023
11 Aug 2023
Seeking expressions of interest — health technology assessment advisory committees
seeking-expressions-of-interest-health-technology-assessment-advisory-committees
02 Aug 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – July 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee – July 2023
01 Aug 2023
International Harmonisation of Ingredient Names (IHIN) - changes to the PBS Schedule effective 1 August 2023
The PBS Schedule has been updated in the 1 August 2023 Schedule to show sole ingredient names for those PBS‑listed medicines for which dual-labelling requirements ceased on 30 April 2023.
01 Aug 2023
PBS Website Update - 1 August 2023
The Schedule of Pharmaceutical Benefits was updated on 1 August 2023. New, Amended and Deleted items can be found on the Summary of Changes page.
28 Jul 2023
Update - Substitution of Budesonide + Formoterol listings
Important Information for Authorised Prescribers and Approved Pharmacists The 1 July 2023 PBS Schedule included approved changes to the listings of the form “budesonide 400 microgram/actuation + formoterol fumarate dihydrate12 microgram/actuation powder for inhalation”